Kazia Therapeutics Ltd (KZIA) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Kazia Therapeutics Ltd (KZIA) following the 2026 Q2 hedge fund 13F filings?

As of today, KZIA has moved +6.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.0% for the XLV sector ETF — an outperformance of +2.4%. Since the quarter end (June 30, 2026), KZIA gained +2.1% vs +9.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Kazia Therapeutics Ltd (KZIA)

36 + Investors. Track Smart Money conviction in KZIA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — KZIA

Based on 23 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds added KZIA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

23 hedge funds hold KZIA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +2200% more funds vs a year ago

fund count last 6Q

+22 new funds entered over the past year (+2200% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 4 quarters from the low — a sharp move.

🟡

Slight buying edge — 58% buying

14 buying10 selling

Last quarter: 14 funds bought or added vs 10 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~7 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 9 → 4 → 12 → 7. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔄

Mostly new holders — 61% entered in last year

■ 17% conviction (2yr+) ■ 22% medium ■ 61% new

Only 4 funds (17%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

➡️

Steady discovery — ~7 new funds/quarter

0 → 9 → 4 → 12 → 7 new funds/Q

New funds entering each quarter: 9 → 4 → 12 → 7. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🌱

Early stage — 70% of holders entered in last year

■ 26% veterans ■ 4% 1-2yr ■ 70% new

Of 23 current holders: 16 (70%) entered in the past year, only 6 (26%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 4% AUM from top-100

4% from top-100 AUM funds

6 of 23 holders rank in the top 100 by AUM, but together hold only 4% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

6.5

out of 10

Moderate Exit Risk

Exit risk score 6.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	36	23	56.52%
13F Shares	4M	2M	130.1%
Total Value	$56M	$13M	333.94%
New Positions	18	7	+11
Increased Positions	10	7	+3
Closed Positions	5	6	-1
Reduced Positions	4	4	-
Total Calls	4	0	100%
Total Puts	1	0	100%
PUT/CALL Ratio	0.25	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

56.52%

13F Shares

130.1%

Total Value

$56M

$13M

333.94%

New Positions

+11

Increased Positions

Closed Positions

-1

Reduced Positions

Total Calls

100%

Total Puts

100%

PUT/CALL Ratio

0.25

0.0

Bullish

Institutional Holders (2026 Q2)

36 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in KZIA. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 KZIA holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Dauntless Investment Group, LLC	3.92%	354,208	$5.0M
2	Stonepine Capital Management, LLC	2.28%	345,179	$4.9M
3	Bleichroeder LP	1.01%	400,000	$5.6M
4	Ikarian Capital, LLC	0.60%	396,201	$5.6M
5	Boxer Capital Management, LLC	0.59%	560,000	$7.9M
6	Westside Investment Management, Inc.	0.09%	47,585	$670K
7	Flputnam Investment Management Co	0.07%	414,958	$5.8M
8	ADAR1 Capital Management, LLC	0.04%	61,550	$867K
9	J. Goldman & Co LP	0.02%	68,491	$964K
10	United Bank	0.02%	12,851	$181K
11	Cooperman Leon G	0.02%	50,000	$704K
12	XTX Topco Ltd	0.01%	31,186	$439K
13	Laird Norton Wetherby Trust Company, LLC	0.00%	12,900	$182K
14	Engineers Gate Manager LP	0.00%	14,975	$211K
15	Ensign Peak Advisors, Inc	0.00%	110,778	$1.6M
16	Point72 Asset Management, L.P.	0.00%	200,300	$2.3M
17	Sequoia Financial Advisors, LLC	0.00%	20,003	$282K
18	GAMMA Investing LLC	0.00%	1,926	$27K
19	Millennium Management LLC	0.00%	101,376	$1.4M
20	Marshall Wace, LLP	0.00%	44,231	$623K
21	Susquehanna International Group, LLP	0.00%	251,700	$3.5M
22	Rockefeller Capital Management L.P.	0.00%	12,700	$179K
23	Barclays plc	0.00%	56,999	$803K
24	BNP Paribas Financial Markets	0.00%	30,090	$424K
25	UBS Group AG	0.00%	81,090	$1.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Kazia Therapeutics Ltd (KZIA)

What does the Smart Money Trend signal show for KZIA?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added KZIA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for KZIA?

Slight buying edge — 58% buying: Last quarter: 14 funds bought or added vs 10 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for KZIA holders?

Smaller funds dominant — 4% AUM from top-100: 6 of 23 holders rank in the top 100 by AUM, but together hold only 4% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held KZIA?

Mostly new holders — 61% entered in last year: Only 4 funds (17%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Kazia Therapeutics Ltd (KZIA) following the 2026 Q2 hedge fund 13F filings?

As of today, KZIA has moved +6.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.0% for the XLV sector ETF — an outperformance of +2.4%. Since the quarter end (June 30, 2026), KZIA has gained +2.1% vs +9.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Kazia Therapeutics Ltd (KZIA)

Smart Money Signals — KZIA

Buying streak — 4 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +2200% more funds vs a year ago

Slight buying edge — 58% buying

Steady new buyers — ~7 new funds per quarter

Mostly new holders — 61% entered in last year

Steady discovery — ~7 new funds/quarter

Early stage — 70% of holders entered in last year

Smaller funds dominant — 4% AUM from top-100

Institutional Sentiment Summary — KZIA

Hedge Fund Ownership: KZIA

Market Analysis: KZIA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: KZIA

Is It Too Late to Buy Kazia Therapeutics Ltd (KZIA) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: KZIA

Statistics: KZIA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Kazia Therapeutics Ltd (KZIA)

Welcome to 13Foresight!